These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25227503)

  • 1. Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment.
    Gomez DS; Sanches-Giraud C; Silva CV; Oliveira AM; da Silva JM; Gemperli R; Santos SR
    J Antibiot (Tokyo); 2015 Mar; 68(3):143-7. PubMed ID: 25227503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
    Li S; Xie F
    Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualised vancomycin doses for paediatric burn patients to achieve PK/PD targets.
    Gomez DS; Campos EV; de Azevedo RP; Silva JM; Ferreira MC; Sanches-Giraud C; Silva CV; Santos SR
    Burns; 2013 May; 39(3):445-50. PubMed ID: 22867735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit.
    Jaruratanasirikul S; Boonpeng A; Nawakitrangsan M; Samaeng M
    Pharmacotherapy; 2021 Jul; 41(7):572-597. PubMed ID: 34080708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System.
    Por ED; Akers KS; Chung KK; Livezey JR; Selig DJ
    J Clin Pharmacol; 2021 Sep; 61(9):1182-1194. PubMed ID: 33811332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
    Corcione S; D'Avolio A; Loia RC; Pensa A; Segala FV; De Nicolò A; Fatiguso G; Romeo M; Di Perri G; Stella M; De Rosa FG
    J Glob Antimicrob Resist; 2020 Mar; 20():22-27. PubMed ID: 31207380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of imipenem in burn patients.
    Dailly E; Kergueris MF; Pannier M; Jolliet P; Bourin M
    Fundam Clin Pharmacol; 2003 Dec; 17(6):645-50. PubMed ID: 15015709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients.
    Lee C; Walker SAN; Walker SE; Seto W; Simor A; Jeschke M
    Burns; 2017 Dec; 43(8):1766-1774. PubMed ID: 28647460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.
    Fournier A; Goutelle S; Que YA; Eggimann P; Pantet O; Sadeghipour F; Voirol P; Csajka C
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
    Couffignal C; Pajot O; Laouénan C; Burdet C; Foucrier A; Wolff M; Armand-Lefevre L; Mentré F; Massias L
    Br J Clin Pharmacol; 2014 Nov; 78(5):1022-34. PubMed ID: 24903189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients.
    Dinh TD; Nguyen HN; Le BH; Nguyen TTT; Nguyen HTL
    Infect Drug Resist; 2022; 15():4575-4583. PubMed ID: 36003989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic analysis of piperacillin in burn patients.
    Jeon S; Han S; Lee J; Hong T; Paek J; Woo H; Yim DS
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3744-51. PubMed ID: 24752260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children.
    Yoshizawa K; Ikawa K; Ikeda K; Ohge H; Morikawa N
    Pediatr Infect Dis J; 2013 Nov; 32(11):1208-16. PubMed ID: 23676856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase].
    Wang H; Peng Y; Xiao G
    Zhonghua Shao Shang Za Zhi; 2000 Dec; 16(6):349-51. PubMed ID: 11876899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem.
    Li Z; Bai J; Wen A; Shen S; Duan M; Li X
    Clin Ther; 2020 Aug; 42(8):1564-1577.e8. PubMed ID: 32741646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.